Please fin enclosed herewith Audited Financial Results for the quarter and Financial Year ended 31st March, 2026.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals reported standalone revenue of Rs 6,651 crore (+10.3% YoY) and consolidated revenue of Rs 7,345 crore (+10.1% YoY) for FY2026. Standalone net profit surged 43.6% to Rs 721 crore while consolidated PAT grew 15.7% to Rs 675 crore. The company recognized exceptional items totalling Rs 48.64 crore for the year, comprising an incremental labour code provision (Rs 48.64 crore) and a write-down of Rs 18.35 crore for the Sikkim manufacturing facility being held for sale. A deferred tax asset of Rs 100.27 crore was recognized due to a change in applicable tax rate and tax credit reassessment. The Board recommended dividend of Rs 12 per share (600%), up from Rs 11 (550%) last year. Auditors issued an unmodified opinion on both standalone and consolidated results.
Strong bottom-line growth with expanding margins — standalone PAT up 43.6% and operating margin improving to 16.82% — signals operational efficiency gains, though the Sikkim facility write-down and labour code charge indicate one-time headwinds. Positive for shareholders with higher dividend payout.